GlassScriptPhysician profile
Jamie M Jarboe
NPI 1417082470
$9,966.90
in general payments reported to CMS, 2019-2025
57 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $4,342 · 2021: $812 · 2022: $613 · 2023: $1,110 · 2024: $1,495 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.48 |
| Education | $179.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $3,938.04 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $584.21 | 2019-2025 | |
| Pfizer INC. | $515.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $347.35 | 2020-2024 | Opdivo, Opdualag, Krazati |
| Seagen INC. | $313.02 | 2019-2023 | Padcev, Adcetris |
| Amgen INC. | $282.11 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $281.98 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $274.14 | 2019-2025 | Tecentriq, Venclexta, Phesgo |
| Janssen Biotech, INC. | $237.98 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $215.12 | 2020-2025 | Enhertu, Tagrisso |
| Iovance Biotherapeutics, INC. | $214.25 | 2024-2025 | Amtagvi |
| Genzyme Corporation | $189.49 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $187.48 | 2019-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $172.00 | 2024-2025 | Injectafer, Enhertu, Vanflyta |
| Abbvie INC. | $156.73 | 2020-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $156.62 | 2019-2025 | Verzenio, Jaypirca |
| Celgene Corporation | $145.20 | 2022-2025 | Pomalyst, Reblozyl |
| Array Biopharma INC | $113.69 | 2019-2022 | |
| Incyte Corporation | $111.59 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $98.92 | 2021-2025 | Trodelvy |
| Exelixis INC. | $94.17 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $92.47 | 2021-2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $80.58 | 2023-2024 | Tivdak, Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $80.19 | 2019-2023 | Imbruvica, Epkinly |
| Coherus Oncology, INC. | $74.01 | 2022-2024 | |
| Glaxosmithkline, LLC. | $71.28 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $61.23 | 2019-2023 | Xospata |
| Pharmaessentia USA Corporation | $59.77 | 2023-2025 | Besremi |
| Clovis Oncology, INC. | $58.45 | 2019-2020 | |
| Eisai INC. | $54.98 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $54.65 | 2019-2025 | Onivyde |
| Emd Serono, INC. | $41.42 | 2019-2023 | Bavencio |
| Jazz Pharmaceuticals INC. | $40.79 | 2019 | |
| Taiho Oncology, INC. | $40.29 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $38.59 | 2019-2023 | Ultomiris |
| Sobi, INC | $36.49 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.14 | 2024 | Iclusig, Fruzaqla |
| Global Blood Therapeutics, INC. | $33.13 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.07 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $29.43 | 2022-2024 | Xpovio |
| Tesaro, INC. | $26.57 | 2019 | |
| Stemline Therapeutics INC. | $23.33 | 2024 | Orserdu |
| Kyowa Kirin, INC. | $22.91 | 2023 | Poteligeo |
| Celltrion USA INC. | $21.96 | 2025 | Vegzelma |
| Accord Healthcare, INC. | $20.57 | 2025 | |
| Recordati_rare_diseases_inc. | $20.46 | 2023 | Sylvant |
| Siemens Medical Solutions USA, INC. | $19.98 | 2022 | |
| Pharmacosmos Therapeutics INC. | $19.73 | 2024 | Monoferric |
| Rigel Pharmaceuticals, INC. | $19.62 | 2024 | Rezlidhia, Tavalisse |
| Sun Pharmaceutical Industries INC. | $18.51 | 2023 | Odomzo, Yonsa |
| Biocon Biologics INC | $17.98 | 2025 | Fulphila |
| Blueprint Medicines Corporation | $17.79 | 2024 | Ayvakit |
| Acceleron Pharma, INC. | $15.99 | 2021 | |
| Immunocore Limited | $15.91 | 2025 | Kimmtrak |
| Sanofi Pasteur INC. | $15.45 | 2024 | |
| Agios Pharmaceuticals, INC. | $14.91 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $14.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Jarboe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.